Hormonal
Tirzepatide (TZP) reduces the risk of four-component major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes (T2DM) and obesity compared to placebo, with the 15mg dose showing the most significant reduction.
If you have T2DM or obesity, Tirzepatide (TZP) can significantly lower your risk of major cardiovascular events (like heart attack or stroke) compared to a placebo. The 15mg dose is the most effective for heart protection, but it also comes with a higher risk of side effects like nausea. Patients with T2DM seem to get more heart benefits and fewer side effects than those with obesity alone. Talk to your doctor about whether the cardiovascular benefits outweigh the potential side effects for you.
Compared to placebo, TZP 5mg, TZP 10mg and TZP 15mg all reduced the incidence of MACE-4 (RR [95% CI], 0.47 [0.23 to 1.12], 0.46 [0.15 to 1.48], 0.38 [0.17 to 0.84], respectively)... TZP 15mg reduced the risk of cardiovascular events more significantly than TZP 5mg, TZP 10mg, GLP-1RAs, and insulin.
Why this rating
Based on a Bayesian network meta-analysis of 14 RCTs with 14,654 participants, providing robust pooled estimates.
Source
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis
xuyang gong et al. · Research Square · 2024
DOI 10.21203/rs.3.rs-4159026/v1
More from this paper
- Tirzepatide increases the risk of total adverse events (TAEs) and adverse events leading to discontinuation (DAEs) in a dose-dependent manner, with the 15mg dose having the highest risk.Good
- Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →